Atea Pharmaceuticals, Inc.
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
Last updated:
Abstract:
A hemi-sulfate salt of the structure: ##STR00001## to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
Status:
Grant
Type:
Utility
Filling date:
1 Jul 2020
Issue date:
19 Jan 2021